New China Foreign Investment Policies Include Biopharma Steps

Data Export, Procurement

 
• By Brian Yang

Amid multinationals' accelerating de-risking and divestment moves in China, the country’s State Council has issued revised policies in the biologics manufacturing and gene therapy area, in a bid to attract foreign investment to the sector. But timely and consistent implementation will be key, an EU trade group says.

Chinese flag
China issues policies to encourage foreign biomedical and CGT investment • Source: Shutterstock

Facing mounting challenges from deflation and other domestic economic pressures, China’s State Council issued on 13 August its latest policies to attract and retain foreign investment.

In the biopharma area, these include support for foreign investment in R&D centers, acceleration of manufacturing activity, support for foreign companies to conduct clinical trials for cell and gene therapies already approved outside China, and improved

So far, cell and gene therapies (CGTs) developed by foreign companies have faced multiple restrictions on development inside China, due to limitations imposed by the tightening of national Human Genetic Resources Management regulations, requirements around the

More from China

More from Asia